News | EP Lab | October 10, 2016

Study Shows Zip Skin Closure System Saves Time in the Cath Lab

Employing system after cardiac implantable electronic device implantation also reduces operator variability compared to absorbable running subcuticular sutures

ZipLine Medical, Zip Surgical Skin Closure, cath lab time savings, PACE study

October 10, 2016 — ZipLine Medical Inc. recently announced results from a study recently published online in Pacing and Clinical Electrophysiology (PACE) showing significant efficiencies when Zip Surgical Skin Closure is used following cardiac implantable electronic device (CIED) implantation. The Zip also demonstrated greater uniformity in closure technique, with no compromise in cosmetic outcomes or patient safety.

The paper reports on the first randomized, controlled, prospective study of the Zip in CIED implantation in 40 patients. In the study, the Zip demonstrated significantly shorter overall closure time (78 ± 6.6 versus 216 ± 21.5 sec.; p < 0.001) and average incision closure time per cm (18 ± 2 versus 50.1 ± 6.7 sec/cm; p < 0.001), with less variance (standard error 2.08 versus 6.72, p < 0.001) when compared to absorbable running subcuticular sutures. Scar cosmesis was equivalent to suturing, and neither group experienced a closure-related adverse event. The article is entitled “Cardiac Device Implant Skin Closure with a Novel Adjustable, Coaptive Tape-Based Device.”

“The significant time savings and reduced variability associated with the Zip device may also improve overall procedure cost and scheduling efficiency,” said Ulrika Birgersdotter-Green, M.D., director, pacemaker and ICD services for the University of California, San Diego School of Medicine and the study’s principal investigator. “Because the device eliminates suturing for the skin closure, this task may potentially be delegated from the operator to further improve workflow efficiency in the procedure lab.”

According to the PACE study authors, closure of the superficial skin layer of surgical incisions has traditionally relied on methods that puncture intact, healthy tissue or introduce a foreign body that is gradually absorbed by the patient’s body. Additionally, suturing requires considerable training and practice, with relatively high inter-surgeon variability for both closure speed and cosmetic outcome. Metal skin staples have been shown to provide a similar time savings versus sutures, but at the cost of puncture scars, increased patient pain and infection risk from additional skin punctures.

The Zip is a non-invasive and easy-to-use device providing protected, secure and well-approximated wound closure with uniformly distributed force along the length of the incision. Clinicians can adjust the tension of the device at any time peri- or post-procedure. Because closure and removal are simple, clinicians can delegate the task to a physician assistant or nurse, and patients may remove it at home, if appropriate. The flexible design is not only comfortable for patients, but often enables them to make quicker progress in their recovery. Because there are no skin punctures with the Zip, scarring is minimal and there are no added channels for infection to enter.

Zip Surgical Skin Closure devices are classified by the U.S. Food and Drug Administration (FDA) as Class I, 510(k) Exempt and have received the CE Mark.

For more information: www.ziplinemedical.com

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo